CompletedNCT01299389
Paliperidone Palmitate Compared With Placebo for Schizophrenia
About this title
Read the official source — NCT01299389Researchers compared Paliperidone palmitate and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Medication studyAges 20+Multiple countries
Understand this study
What did researchers investigate?
Researchers compared Paliperidone palmitate and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 20 years. Other eligibility criteria applied.
- Listed locations
- Fujioka and 55 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateOctober 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 323
- Sponsor
- Janssen Pharmaceutical K.K.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Japan, South Korea, Taiwan
- Age range
- Over 20 Years
- Official registry ID
- NCT01299389
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedFujioka, Japan · Fujisawa, Japan · Fukui, Japan
53 more locations
- Fukuoka, Japan
- Hadano, Japan
- Ichikawa, Japan
- Itoman, Japan
- Kanzaki, Japan
- Kashihara, Japan
- Kasuya, Japan
- Kawasaki, Japan
- Kitagunma, Japan
- Kitakyushu, Japan
- Kobe, Japan
- Kodaira, Japan
- Koshigaya, Japan
- Kumagaya, Japan
- Kumamoto, Japan
- Kurayoshi, Japan
- Kure, Japan
- Kurume, Japan
- Mitaka, Japan
- Miyazaki, Japan
- Moriguchi, Japan
- Nanyō, Japan
- Nishinomiya, Japan
- Ohta, Japan
- Okinawa, Japan
- Oyabe, Japan
- Sakai, Japan
- Shibukawa, Japan
- Takatsuki, Japan
- Tamana, Japan
- Tokyo, Japan
- Toyama, Japan
- Toyoake, Japan
- Urasoe, Japan
- Yatsushiro, Japan
- Yokkaichi, Japan
- Yokohama, Japan
- Busan, South Korea
- Chungcheongbuk-Do, South Korea
- Daegu, South Korea
- Deajun, South Korea
- Incheon, South Korea
- Inchun, South Korea
- Jeonju, South Korea
- Seongnam, South Korea
- Seoul, South Korea
- Bali Township, Taipei County, Taiwan
- Changhua, Taiwan
- Hualien City, Taiwan
- Kaohsiung City, Taiwan
- Tainan, Taiwan
- Taipei, Taiwan
- Taoyuan, Taiwan
Questions about this study
What did researchers investigate?
Researchers compared Paliperidone palmitate and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Janssen Pharmaceutical K.K., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Paliperidone palmitate and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 20 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 6-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENT SUBJECTS WITH SCHIZOPHRENIA
Lurasidone Compared With Quetiapine for Acute Psychosis in Schizophrenia